
A phase III, multicentre, randomized, double-blind, placebo-controlled trial (True North) investigated ozanimod (a selective sphingosine-1-phosphate receptor modulator) in patients with moderately to severely active ulcerative colitis. The incidence of clinical response was also significantly higher with ozanimod than placebo in both induction and maintenance phases. The overall incidence of adverse events was similar between groups in the induction phase, but higher in the ozanimod group in the maintenance period.
Like
Save
Share